search
Back to results

Type 2 Diabetes Intervention by Gut Microbiota-directed Diet -a Open Labelled RCT (T2D)

Primary Purpose

Type 2 Diabetes

Status
Recruiting
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Food
Sponsored by
Qilu Hospital of Shandong University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for Type 2 Diabetes

Eligibility Criteria

30 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Newly diagnosed type 2 diabetes mellitus patients who have been diagnosed or screened for treatment without any hypoglycemic drugs;
  • 6.5%≤HbA1c≤8.5%;
  • FPG<10.0mmol/L;
  • BMI≥24;

Exclusion Criteria:

  • suspected other types of diabetes
  • Moderate stroke occurred within one year;
  • Frequent diarrhea or constipation in the past 3 months (more than 4 times / week);
  • Acute complications occurred in the past 3 months, such as infection, ketosis and acidosis;
  • Pregnant and lactating women (or women who are currently trying to conceive, or who are likely to have children and do not use contraceptives);
  • Drinking (1 weeks of drinking more than 5 times, on average 2 two Baijiu or half Jin of yellow wine or 5 bottles of beer above);
  • Those who have received drug treatment for the following diseases in the past three months: cholecystitis, peptic ulcer, urinary tract infection, acute pyelonephritis, cystitis, hyperthyroidism and other thyroid dysfunction;
  • Gastrointestinal surgery (except appendicitis and hernia surgery);
  • Antibiotics have been used in the past 3 months for 3 days or more;
  • Physical methods, such as liposuction or gastrointestinal reconstruction, have been used to lose weight in the past 3 months;
  • Physical disability, or inability to take care of themselves, recall and answer questions clearly due to other reasons;
  • Anemia: hemoglobin < 10g / dl;
  • Patients with severe liver diseases such as chronic hepatitis, persistent hepatitis and cirrhosis, and hepatitis B virus surface antigen (HBsAg) positive and abnormal liver function (serum alanine aminotransferase and aspartate aminotransferase are 2.5 times the normal value).
  • Other serious diseases, such as malignant tumors, serious mental diseases, serious infectious diseases, etc;
  • Patients who are participating in other intervention studies;
  • In the judgment of the study physician, there are any conditions that affect the study compliance, such as:Alcohol or drug abuse in the past 12 months; Serious adverse drug treatment compliance in the past 12 months; The residence is far away from the research center, or it is planned to move far away or travel frequently in the next year; The clinical diagnosis of dementia or the judgment of cognitive function by the research physician will affect the research compliance; Other medical, psychological or behavioral factors that affect the study compliance are judged by the study physician.

Sites / Locations

  • Qilu Hospital of Shandong UniversityRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

Health

Disease

Arm Description

Outcomes

Primary Outcome Measures

changes of HbA1c compared with baseline
changes of HbA1c compared with baseline
remission rate
remission rate of T2D by ADA guideline;ratio of subjects whose blood glucose can reach completely normal without drug intervention

Secondary Outcome Measures

control rate
Proportion of subjects with HbA1c < 7.0%
blood lipid profile
Changes of blood lipids (total cholesterol, triglyceride, high density lipoprotein cholesterol, low density lipoprotein cholesterol) relative to baseline

Full Information

First Posted
September 12, 2022
Last Updated
March 22, 2023
Sponsor
Qilu Hospital of Shandong University
search

1. Study Identification

Unique Protocol Identification Number
NCT05541237
Brief Title
Type 2 Diabetes Intervention by Gut Microbiota-directed Diet -a Open Labelled RCT
Acronym
T2D
Official Title
Type 2 Diabetes Intervention by Gut Microbiota-directed Diet -a Open Labelled Randomized Controlled Trials
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
August 17, 2022 (Actual)
Primary Completion Date
September 5, 2023 (Anticipated)
Study Completion Date
September 8, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Qilu Hospital of Shandong University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study is a randomized, open labelled, placebo-controlled clinical trial. The main purpose is to verify the superior effect of gut microbiota directed diet intervention over standard diet intervention by evaluating the changes of HbA1c relative to baseline at 16 weeks and 28 weeks of follow-up.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes

7. Study Design

Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
200 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Health
Arm Type
No Intervention
Arm Title
Disease
Arm Type
Experimental
Intervention Type
Dietary Supplement
Intervention Name(s)
Food
Intervention Description
Food
Primary Outcome Measure Information:
Title
changes of HbA1c compared with baseline
Description
changes of HbA1c compared with baseline
Time Frame
28 weeks
Title
remission rate
Description
remission rate of T2D by ADA guideline;ratio of subjects whose blood glucose can reach completely normal without drug intervention
Time Frame
28 weeks
Secondary Outcome Measure Information:
Title
control rate
Description
Proportion of subjects with HbA1c < 7.0%
Time Frame
at 16 weeks of treatment and 28 weeks of follow-up
Title
blood lipid profile
Description
Changes of blood lipids (total cholesterol, triglyceride, high density lipoprotein cholesterol, low density lipoprotein cholesterol) relative to baseline
Time Frame
at 16 weeks of treatment and 28 weeks of follow-up

10. Eligibility

Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Newly diagnosed type 2 diabetes mellitus patients who have been diagnosed or screened for treatment without any hypoglycemic drugs; 6.5%≤HbA1c≤8.5%; FPG<10.0mmol/L; BMI≥24; Exclusion Criteria: suspected other types of diabetes Moderate stroke occurred within one year; Frequent diarrhea or constipation in the past 3 months (more than 4 times / week); Acute complications occurred in the past 3 months, such as infection, ketosis and acidosis; Pregnant and lactating women (or women who are currently trying to conceive, or who are likely to have children and do not use contraceptives); Drinking (1 weeks of drinking more than 5 times, on average 2 two Baijiu or half Jin of yellow wine or 5 bottles of beer above); Those who have received drug treatment for the following diseases in the past three months: cholecystitis, peptic ulcer, urinary tract infection, acute pyelonephritis, cystitis, hyperthyroidism and other thyroid dysfunction; Gastrointestinal surgery (except appendicitis and hernia surgery); Antibiotics have been used in the past 3 months for 3 days or more; Physical methods, such as liposuction or gastrointestinal reconstruction, have been used to lose weight in the past 3 months; Physical disability, or inability to take care of themselves, recall and answer questions clearly due to other reasons; Anemia: hemoglobin < 10g / dl; Patients with severe liver diseases such as chronic hepatitis, persistent hepatitis and cirrhosis, and hepatitis B virus surface antigen (HBsAg) positive and abnormal liver function (serum alanine aminotransferase and aspartate aminotransferase are 2.5 times the normal value). Other serious diseases, such as malignant tumors, serious mental diseases, serious infectious diseases, etc; Patients who are participating in other intervention studies; In the judgment of the study physician, there are any conditions that affect the study compliance, such as:Alcohol or drug abuse in the past 12 months; Serious adverse drug treatment compliance in the past 12 months; The residence is far away from the research center, or it is planned to move far away or travel frequently in the next year; The clinical diagnosis of dementia or the judgment of cognitive function by the research physician will affect the research compliance; Other medical, psychological or behavioral factors that affect the study compliance are judged by the study physician.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ruxing Zhao, doctor
Phone
865318219322
Email
rusingstar@163.com
First Name & Middle Initial & Last Name or Official Title & Degree
Jianjun Sun, BS
Phone
8618916149662
Facility Information:
Facility Name
Qilu Hospital of Shandong University
City
Jinan
State/Province
Shandong
ZIP/Postal Code
250012
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yujing Sun, PhD
Phone
08653182169321

12. IPD Sharing Statement

Learn more about this trial

Type 2 Diabetes Intervention by Gut Microbiota-directed Diet -a Open Labelled RCT

We'll reach out to this number within 24 hrs